Derby pharma firm sold to listed investor

N4 Pharma, the Derby pharma firm, has been sold to listed investment firm Onzima for an undisclosed sum.

N4 Pharma, founded in 2014, is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

Nigel Theobald, CEO of N4 Pharma, said: “Today marks an important step forward for N4 Pharma and we are delighted at the support of investors at this exciting time.

“Bringing a new drug to market is inherently risky, time consuming and extremely costly. However, the established process of reformulating already established drugs reduces the risk, cost and length of time it takes to bring new versions of these drugs to market. Following completion of the transaction, the net funds raised will enable N4 Pharma to accelerate its work on the reformulation of generic drugs and those that are coming to the end of their patent protection, each with attractive commercial opportunities, as well as expand our product portfolio.

“We look forward to life as a publicly traded company and will continue to update shareholders on progress in due course.”